Moderna, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines. Its primary revenue streams come from the sale of vaccines for infectious diseases, particularly its COVID-19 vaccine, which has generated a significant portion of its revenue, estimated at over 60%. Other vaccine products include those for flu and respiratory syncytial virus, alongside various cancer and rare disease therapeutics. The company operates in the United States, Europe, and internationally, and its strategic alliances with major pharmaceutical companies and health organizations support its research and development efforts. Factors that may support its endurance include its innovative mRNA technology and established partnerships, while reliance on a limited number of products, particularly the COVID-19 vaccine, may pose risks to long-term sustainability.
—
Moderna, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines. Its primary revenue streams come from the sale of vaccines for infectious diseases, particularly its COVID-19 vaccine, which has generated a significant portion of its revenue, estimated at over 60%. Other vaccine products include those for flu and respiratory syncytial virus, alongside various cancer and rare disease therapeutics. The company operates in the United States, Europe, and internationally, and its strategic alliances with major pharmaceutical companies and health organizations support its research and development efforts. Factors that may support its endurance include its innovative mRNA technology and established partnerships, while reliance on a limited number of products, particularly the COVID-19 vaccine, may pose risks to long-term sustainability.
—
Daily adjusted close
Moderna, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines. Its primary revenue streams come from the sale of vaccines for infectious diseases, particularly its COVID-19 vaccine, which has generated a significant portion of its revenue, estimated at over 60%. Other vaccine products include those for flu and respiratory syncytial virus, alongside various cancer and rare disease therapeutics. The company operates in the United States, Europe, and internationally, and its strategic alliances with major pharmaceutical companies and health organizations support its research and development efforts. Factors that may support its endurance include its innovative mRNA technology and established partnerships, while reliance on a limited number of products, particularly the COVID-19 vaccine, may pose risks to long-term sustainability.